Tyler James 4
4 · SANUWAVE Health, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Tyler James
Director
Transactions
- Disposition to Issuer
Common Stock Purchase Warrant (right to buy)
2024-10-18−3,000→ 0 totalExercise: $25.13From: 2022-08-05Exp: 2027-08-05→ Common Stock (3,000 underlying) - Award
Common Stock Purchase Warrant (right to buy)
2022-08-05+3,000→ 3,000 totalExercise: $15.00From: 2022-08-05Exp: 2027-08-05→ Common Stock (3,000 underlying) - Disposition to Issuer
Common Stock Purchase Warrant (right to buy)
2024-10-18−3,000→ 0 totalExercise: $15.00From: 2022-08-05Exp: 2027-08-05→ Common Stock (3,000 underlying) - Award
Common Stock Purchase Warrant (right to buy)
2022-08-05+3,000→ 3,000 totalExercise: $25.13From: 2022-08-05Exp: 2027-08-05→ Common Stock (3,000 underlying) - Award
Common Stock
2024-10-18+2,700→ 6,150 total - Award
Common Stock
2024-10-18+2,550→ 8,700 total - Award
Future Advance Convertible Promissory Note
2022-08-05$45000.00/shExercise: $15.00From: 2022-08-05Exp: 2023-08-05→ Common Stock (3,000 underlying) - Conversion
Future Advance Convertible Promissory Note
2023-08-05→ 0 totalExercise: $15.00From: 2022-08-05Exp: 2023-08-05→ Common Stock (3,450 underlying) - Award
Stock Option (right to buy)
2024-10-22+41,333→ 41,333 totalExercise: $14.20Exp: 2034-10-22→ Common Stock (41,333 underlying) - Award
Stock Option (right to buy)
2024-12-31+1,559→ 1,559 totalExercise: $22.76Exp: 2029-12-31→ Common Stock (1,559 underlying) - Conversion
Common Stock
2023-08-05$15.00/sh+3,450$51,750→ 3,450 total
Footnotes (5)
- [F1]Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share.
- [F2]On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's warrants were exchanged for an aggregate of 5,250 shares of common stock pursuant to a letter agreement between the reporting person and the Company.
- [F3]On August 5, 2022, in exchange for $45,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $45,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 3,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 3,000 shares of common stock at an exercise price of approximately $25.13 per share).
- [F4]Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date.
- [F5]Options were fully vested at the grant date.